Follow The Filings

INFU InfuSystems

InfuSystems earnings company data as of 10:00 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by INFU's executives, directors and 10% owners in the last 12 months, from their Form 4s

All INFU insider trades
  • $150K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Paul Andrew Gendron Director
    Buy
    $44K 5,000 shares at $8.88 +7.7% to stake
    Traded May 8 Filed May 12
    ↗
  2. Carrie Lachance CEO
    Buy
    $26K 3,000 shares at $8.71 +1.3% to stake
    Traded May 8–11 Filed May 12
    ↗
  3. Barry G Steele CFO
    Buy
    $61K 7,000 shares at $8.71 +7.8% to stake
    Traded May 8 Filed May 12
    ↗
  4. Barry G Steele CFO
    Buy
    $19K 2,064 shares at $9.16 +2.4% to stake
    Traded Mar 2 Filed Mar 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 share withholdings for taxes, 8 option exercises, 4 stock grants, and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 7.01 Filing Doc
8-K 2.02 Filing Doc
8-K 7.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01 Filing Doc
8-K 7.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07 Filing Doc
10-Q Filing Doc
8-K 2.02 Filing Doc
8-K 7.01 Filing Doc
DEF 14A Filing Doc
8-K 4.01 Filing Doc
8-K 7.01 Filing Doc
10-K Filing Doc
8-K 7.01 Filing Doc
8-K 2.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.